{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T21:35:27Z","timestamp":1774474527701,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.vaccine.2021.03.075","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T20:14:28Z","timestamp":1617308068000},"page":"2526-2536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0\u0394NLS vaccine against ocular HSV-1 challenge"],"prefix":"10.1016","volume":"39","author":[{"given":"Daniel J.J.","family":"Carr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda N.","family":"Berube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Filiberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz B.","family":"Gmyrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2021.03.075_b0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.survophthal.2012.01.005","article-title":"Herpes simplex epithelial and stromal keratitis: an epidemiologic update","volume":"57","author":"Farooq","year":"2012","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.075_b0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00018-018-2938-1","article-title":"Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea","volume":"76","author":"Koujah","year":"2019","journal-title":"Cell Mol Life Sci: CMLS"},{"key":"10.1016\/j.vaccine.2021.03.075_b0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.preteyeres.2013.06.003","article-title":"Type I interferon and lymphangiogenesis in the HSV-1 infected cornea - are they beneficial to the host?","volume":"36","author":"Bryant-Hudson","year":"2013","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.075_b0020","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1167\/iovs.14-15596","article-title":"Degeneration and regeneration of corneal nerves in response to HSV-1 infection","volume":"56","author":"Chucair-Elliott","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.vaccine.2021.03.075_b0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.preteyeres.2012.08.002","article-title":"Herpes keratitis","volume":"32","author":"Rowe","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.vaccine.2021.03.075_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2012.07.002","article-title":"Pathogenesis of herpes stromal keratitis\u2013a focus on corneal neovascularization","volume":"33","author":"Gim\u00e9nez","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.vaccine.2021.03.075_b0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.exer.2019.04.022","article-title":"Development of lacrimal gland inflammation in the mouse model of herpes stromal keratitis","volume":"184","author":"Rao","year":"2019","journal-title":"Exp Eye Res"},{"issue":"16","key":"10.1016\/j.vaccine.2021.03.075_b0040","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00314-19","article-title":"Ocular glands become infected secondarily to infectious keratitis and play a role in corneal resistance to infection","volume":"93","author":"Montgomery","year":"2019","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.075_b0045","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ophtha.2020.01.037","article-title":"Herpetic eye disease study: a controlled trial of topical corticosteroids for herpes simplex stromal keratitis","volume":"127","author":"Wilhelmus","year":"2020","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.075_b0050","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1189\/jlb.4A1116-459R","article-title":"Long-term consequences of topical dexamethasone treatment during acute corneal HSV-1 infection on the immune system","volume":"101","author":"Chucair-Elliott","year":"2017","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.075_b0055","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/j.ajpath.2016.06.007","article-title":"IL-6 contributes to corneal nerve degeneration after herpes simplex virus Type I infection","volume":"186","author":"Chucair-Elliott","year":"2016","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.075_b0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/02713688709020085","article-title":"Protective immunity against herpetic ocular disease in an outbred mouse model","volume":"6","author":"Metcalf","year":"1987","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.075_b0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17469899.2015.1004315","article-title":"The current state of vaccine development for ocular HSV-1 infection","volume":"10","author":"Royer","year":"2015","journal-title":"Expert Rev Ophthalmol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.075_b0070","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.4049\/jimmunol.0902322","article-title":"A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes","volume":"184","author":"Chentoufi","year":"2010","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"7","key":"10.1016\/j.vaccine.2021.03.075_b0075","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.vaccine.2010.12.031","article-title":"An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice","volume":"29","author":"Hu","year":"2011","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.075_b0080","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.4049\/jimmunol.1301415","article-title":"Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes","volume":"191","author":"Dervillez","year":"2013","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.075_b0085","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.4049\/jimmunol.1402606","volume":"194","author":"Srivastava","year":"2015","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.075_b0090","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01793-16","volume":"91","author":"Srivastava","year":"2017","journal-title":"J Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2021.03.075_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01036-18","article-title":"Attenuated Herpes Simplex Virus 1 (HSV-1) expressing a mutant form of ICP6 stimulates a strong immune response that protects mice against HSV-1-induced corneal disease","volume":"92","author":"Davido","year":"2018","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.075_b0100","doi-asserted-by":"crossref","first-page":"e0228252","DOI":"10.1371\/journal.pone.0228252","article-title":"Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis","volume":"15","author":"Naidu","year":"2020","journal-title":"PLoS ONE"},{"issue":"13","key":"10.1016\/j.vaccine.2021.03.075_b0105","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00335-20","article-title":"A single-cycle glycoprotein d deletion viral vaccine candidate, \u0394gD-2, elicits polyfunctional antibodies that protect against ocular herpes simplex virus","volume":"94","author":"Ramsey","year":"2020","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2021.03.075_b0110","doi-asserted-by":"crossref","first-page":"e1008703","DOI":"10.1371\/journal.ppat.1008703","article-title":"A HSV1 mutant leads to an attenuated phenotype and induces immunity with a protective effect","volume":"16","author":"Xu","year":"2020","journal-title":"PLoS Pathog"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.075_b0115","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1128\/JVI.00517-16","article-title":"A highly efficacious herpes simplex virus 1 vaccine blocks viral pathogenesis and prevents corneal immunopathology via humoral immunity","volume":"90","author":"Royer","year":"2016","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.075_b0120","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41385-019-0131-y","article-title":"Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection","volume":"12","author":"Royer","year":"2019","journal-title":"Mucosal Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.03.075_b0125","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02342-16","article-title":"Impact of Type I interferon on the safety and immunogenicity of an experimental live-attenuated herpes simplex Virus 1 vaccine in mice","volume":"91","author":"Royer","year":"2017","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.075_b0130","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.4049\/jimmunol.1700316","article-title":"The neonatal Fc receptor and complement fixation facilitate prophylactic vaccine-mediated humoral protection against viral infection in the ocular mucosa","volume":"199","author":"Royer","year":"2017","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"6203","key":"10.1016\/j.vaccine.2021.03.075_b0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/337184a0","article-title":"An Fc receptor structurally related to MHC class I antigens","volume":"337","author":"Simister","year":"1989","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.vaccine.2021.03.075_b0140","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/eji.1830260718","article-title":"An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta","volume":"26","author":"Simister","year":"1996","journal-title":"Eur J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2021.03.075_b0145","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.4049\/jimmunol.157.8.3317","article-title":"Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport","volume":"157","author":"Leach","year":"1996","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"10.1016\/j.vaccine.2021.03.075_b0150","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2567.1996.d01-775.x","article-title":"Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn","volume":"89","author":"Israel","year":"1996","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.075_b0155","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.075_b0160","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.20020400","article-title":"Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung","volume":"196","author":"Spiekermann","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.075_b0165","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fimmu.2013.00200","article-title":"Antibodies and their receptors: different potential roles in mucosal defense","volume":"4","author":"Horton","year":"2013","journal-title":"Front Immunol"},{"issue":"45","key":"10.1016\/j.vaccine.2021.03.075_b0170","doi-asserted-by":"crossref","first-page":"18406","DOI":"10.1073\/pnas.1115348108","article-title":"Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport","volume":"108","author":"Bai","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.075_b0175","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1167\/iovs.07-0871","article-title":"Mapping of the neonatal Fc receptor in the rodent eye","volume":"49","author":"Kim","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.vaccine.2021.03.075_b0180","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/intimm\/dxl110","article-title":"Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease","volume":"18","author":"Petkova","year":"2006","journal-title":"Int Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.075_b0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/viro.1997.8806","article-title":"Acyclovir blocks cytokine gene expression in trigeminal ganglia latently infected with herpes simplex virus type 1","volume":"238","author":"Halford","year":"1997","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.075_b0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/iovs.61.10.24","article-title":"Loss of osteopontin expression reduces HSV-1-induced corneal opacity","volume":"61","author":"Filiberti","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.vaccine.2021.03.075_b0195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1084\/jem.20091385","article-title":"VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis","volume":"207","author":"Wuest","year":"2010","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.075_b0200","doi-asserted-by":"crossref","first-page":"608","DOI":"10.4049\/immunohorizons.2000060","article-title":"Distinguishing features of high- and low-dose vaccine against ocular HSV-1 infection correlates with recognition of specific HSV-1-encoded proteins","volume":"4","author":"Carr","year":"2020","journal-title":"Immunohorizons"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.075_b0205","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.4049\/jimmunol.1600207","article-title":"Resident T cells are unable to control herpes simplex virus-1 activity in the brain ependymal region during latency","volume":"197","author":"Menendez","year":"2016","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.075_b0210","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.4049\/jimmunol.1203265","article-title":"Microglia and a functional type I IFN pathway are required to counter HSV-1-driven brain lateral ventricle enlargement and encephalitis","volume":"190","author":"Conrady","year":"2013","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"1-2","key":"10.1016\/j.vaccine.2021.03.075_b0215","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jneuroim.2014.08.005","article-title":"Enhanced resistance of CXCR3 deficient mice to ocular HSV-1 infection is due to control of replication in the brain ependyma","volume":"276","author":"Kroll","year":"2014","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.075_b0220","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/mi.2017.26","article-title":"Fibroblast growth factor-2 drives and maintains progressive corneal neovascularization following HSV-1 infection","volume":"11","author":"Gurung","year":"2018","journal-title":"Mucosal Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.075_b0225","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.immuni.2004.05.007","article-title":"Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells","volume":"20","author":"Yoshida","year":"2004","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.075_b0230","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1073\/pnas.1012861108","article-title":"Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection","volume":"108","author":"Li","year":"2011","journal-title":"PNAS"},{"issue":"24","key":"10.1016\/j.vaccine.2021.03.075_b0235","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1073\/pnas.1019037108","article-title":"Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells","volume":"108","author":"Baker","year":"2011","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.075_b0240","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/icb.2016.80","article-title":"Cornea lymphatics drive the CD8(+) T-cell response to herpes simplex virus-1","volume":"95","author":"Gurung","year":"2017","journal-title":"Immunol Cell Biol"},{"issue":"39","key":"10.1016\/j.vaccine.2021.03.075_b0245","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1021\/bi9913505","article-title":"Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution","volume":"38","author":"Martin","year":"1999","journal-title":"Biochemistry"},{"issue":"14","key":"10.1016\/j.vaccine.2021.03.075_b0250","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1073\/pnas.0700337104","article-title":"Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy","volume":"104","author":"Prabhat","year":"2007","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2021.03.075_b0255","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2021.03.075_b0260","series-title":"Fc Receptors","first-page":"29","article-title":"Emerging Roles for the FCRL Family Members in Lymphocyte Biology and Disease","author":"Li","year":"2014"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.075_b0265","doi-asserted-by":"crossref","first-page":"e1005253","DOI":"10.1371\/journal.ppat.1005253","article-title":"TRIM21 promotes cGAS and RIG-I sensing of viral genomes during infection by antibody-opsonized virus","volume":"11","author":"Watkinson","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.03.075_b0270","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3389\/fmicb.2020.00703","article-title":"TRIM21 Aggravates Herpes Simplex Virus Epithelial Keratitis by Attenuating STING-IRF3-Mediated Type I Interferon Signaling","volume":"11","author":"Tan","year":"2020","journal-title":"Front Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.03.075_b0275","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.4049\/jimmunol.1003735","article-title":"Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL\/6 mice","volume":"186","author":"St. Leger","year":"2011","journal-title":"Journal of immunology (Baltimore, Md: 1950)"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.075_b0280","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4161\/mabs.3.5.17023","article-title":"Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies","volume":"3","author":"Kacskovics","year":"2011","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.075_b0285","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1099\/vir.0.058461-0","article-title":"Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation","volume":"95","author":"Garg","year":"2014","journal-title":"J General Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.075_b0290","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.immuni.2017.07.009","article-title":"Fc\u03b3 receptor function and the design of vaccination strategies","volume":"47","author":"Bournazos","year":"2017","journal-title":"Immunity"},{"issue":"24","key":"10.1016\/j.vaccine.2021.03.075_b0295","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01000-20","article-title":"Herpes Simplex Virus 1 (HSV-1) 0\u0394NLS live-attenuated vaccine protects against ocular HSV-1 infection in the absence of neutralizing antibody in HSV-1 gB T cell receptor-specific transgenic mice","volume":"94","author":"Gmyrek","year":"2020","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.075_b0300","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/mi.2015.124","article-title":"A STING-dependent innate-sensing pathway mediates resistance to corneal HSV-1 infection via upregulation of the antiviral effector tetherin","volume":"9","author":"Royer","year":"2016","journal-title":"Mucosal Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21003790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21003790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:54:54Z","timestamp":1759402494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21003790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":60,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0264410X21003790"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0\u0394NLS vaccine against ocular HSV-1 challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}